Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes

Publication date: Available online 23 May 2019Source: Cancer CellAuthor(s): Ruidong Xue, Lu Chen, Chong Zhang, Masashi Fujita, Ruoyan Li, Shu-Mei Yan, Choon Kiat Ong, Xiwen Liao, Qiang Gao, Shota Sasagawa, Yanmeng Li, Jincheng Wang, Hua Guo, Qi-Tao Huang, Qian Zhong, Jing Tan, Lisha Qi, Wenchen Gong, Zhixian Hong, Meng LiSummaryWe performed genomic and transcriptomic sequencing of 133 combined hepatocellular and intrahepatic cholangiocarcinoma (cHCC-ICC) cases, including separate, combined, and mixed subtypes. Integrative comparison of cHCC-ICC with hepatocellular carcinoma and intrahepatic cholangiocarcinoma revealed that combined and mixed type cHCC-ICCs are distinct subtypes with different clinical and molecular features. Integrating laser microdissection, cancer cell fraction analysis, and single nucleus sequencing, we revealed both mono- and multiclonal origins in the separate type cHCC-ICCs, whereas combined and mixed type cHCC-ICCs were all monoclonal origin. Notably, cHCC-ICCs showed significantly higher expression of Nestin, suggesting Nestin may serve as a biomarker for diagnosing cHCC-ICC. Our results provide important biological and clinical insights into cHCC-ICC.Graphical Abstract
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research

Related Links:

Authors: Kreidieh M, Zeidan YH, Shamseddine A Abstract Treatment recommendations for primary liver malignancies, including hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are complex and require a multidisciplinary approach. Despite surgical options that are potentially curative, options for nonsurgical candidates include systemic therapy, radiotherapy (RT), transarterial chemoembolization (TACE), and radiofrequency ablation (RFA). Stereotactic Body Radiation Therapy (SBRT) is now in routine use for the treatment of lung cancer, and there is growing evidence supporting its use in liver tumors. SBRT has...
Source: Journal of Oncology - Category: Cancer & Oncology Tags: J Oncol Source Type: research
Publication date: 10 June 2019Source: Cancer Cell, Volume 35, Issue 6Author(s): Marco Seehawer, Luana D’Artista, Lars ZenderPrognosis of combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma, a type of primary liver cancer comprising areas with HCC and ICC histopathology, is dismal, and it is unclear if such tumors develop clonally and how they should be treated. In this issue of Cancer Cell, Xue et al. (2019) provide answers to these questions.
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
This article summarizes the milestones in the development of erdafitinib leading to this first approval for the treatment of urothelial carcinoma.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
Conclusion: HBV promotes the aggressiveness of HCC in Chinese. Contributions of HBV to ICC and other etiological factors to HCC might be indirect via arousing non-resolving inflammation.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conditions:   Stage III Hepatocellular Carcinoma AJCC v8;   Stage III Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIA Hepatocellular Carcinoma AJCC v8;   Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IIIB Hepatocellular Carcinoma AJCC v8;   Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IV Hepatocellular Carcinoma AJCC v8;   Stage IV Intrahepatic Cholangiocarcinoma AJCC v8;   Stage IVA Hep...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: The landscape of DDR mutations and their association with genetic and clinicopathological features demonstrated that PLC patients with altered DDR genes may be rational candidates for precision oncology treatment. PMID: 31068370 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Rationale: Wilson disease (WD) is an autosomal recessive hereditary disease in which the patient usually has a reduced risk of developing cancer. In particular, with the exception of hepatocellular carcinoma and cholangiocarcinoma, the incidence of cancer is significantly lower in WD patients compared with the general population. This case study presents a rare case of WD complicated with primary breast cancer. Patient concerns: A 40-year-old woman who was diagnosed with WD at 25 years of age found a lump in her left breast. She has a family history of cancer. Diagnoses: Ultrasound and mammography results were high...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Hepatocellular Carcinoma | Liver Cancer | Men | Molecular Biology